Advanced search
Start date

Potential evaluation of cetuximab-modified mesoporous silica nanoparticles as docetaxel carrier to prostate cancer treatment.

Grant number: 18/25377-3
Support type:Scholarships in Brazil - Post-Doctorate
Effective date (Start): January 01, 2020
Effective date (End): December 31, 2021
Field of knowledge:Engineering - Materials and Metallurgical Engineering
Principal Investigator:Marlus Chorilli
Grantee:Rafael Miguel Sábio
Home Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil


Prostate cancer (PC) is one of the most non-contagious diseases that affects the male population in the world. Although clinically effective, the chemotherapy treatment with docetaxel (DTX) is associated with the development of resistance in more advanced stages of the disease. Beyond that, DTX presents low aqueous solubility and drawbacks related to its pharmacokinetics. Mesoporous silica nanoparticles have attracted great interest due to their high chemical stability, large surface area and tunable pores diameters and volumes, allowing the incorporation of large amounts of drugs, protecting them from deactivation and degradation processes besides avoids premature release acting as an excellent nanocarrier. In addition, the hydroxyls groups available on its surface allows the conjugation of molecules such as the monoclonal antibody cetuximab (CTE) which binds to the overexpressed Enhanced Growth Factor Receptor (EGFR) in many prostate tumors, representing a potential strategy for the treatment of prostate cancer associated to DTX. Taking into account all aforementioned, the goal of this research project consist on develop intelligent nanoplatforms based on mesoporous silica nanoparticles functionalized with CTE as DTX carriers to PC treatment. This proposal aims to overcome drawbacks as low internalization, premature release before to reach the region of interest, several side effects to the patient and low effectiveness of the current treatments. In order to evaluate these parameters, materials characterization and methods validation will be carried out as well as in vitro assays using PC-3 and DU145 cells line models and in vivo assays from animal model aiming to prove the efficacy of the new nanocarriers.

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
SABIO, RAFAEL MIGUEL; MENEGUIN, ANDREIA BAGLIOTTI; DOS SANTOS, ALINE MARTINS; MONTEIRO, ANDREIA SOFIA; CHORILLI, MARLUS. Exploiting mesoporous silica nanoparticles as versatile drug carriers for several routes of administration. Microporous and Mesoporous Materials, v. 312, JAN 2021. Web of Science Citations: 0.

Please report errors in scientific publications list by writing to: